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Abstract
Background The SarQoL® questionnaire was specifically designed to measure quality of life (QoL) in sarcopenia. Frailty and
sarcopenia have areas of overlap, notably weak muscle strength and slow gait speed, which may mean that the SarQoL could
provide a measure of QoL in frailty. This study aimed to evaluate the clinimetric properties of the SarQoL questionnaire in
physical frailty using the Fried criteria.
Methods Analyses were carried out on data from the Sarcopenia and Physical impairment with advancing Age study. Frailty
was assessed with the Fried criteria and QoL with the SarQoL, the Short-Form 36-Item, and the EuroQoL 5-Dimension (EQ-5D)
questionnaires. We evaluated discriminative power (with the Kruskal–Wallis analysis of variance test), internal consistency
(with Cronbach’s alpha), construct validity (through hypotheses testing), test–retest reliability (with the intraclass correlation
coefficient), measurement error (calculating standard error of measurement and smallest detectable change), and
responsiveness (through hypotheses testing and standardized response mean).
Results In total, 382 participants were included for the validation and 117 for the responsiveness evaluation. They had a
median age of 73 (69–79) years, took 5 (3–8) drugs, and had 4 (3–5) co-morbidities. There were more women (n = 223;
58.4%) than men and, in total, 172 (45%) robust, 167 (44%) pre-frail, and 43 (11%) frail participants. Discriminative power
was confirmed when significantly lower (P < 0.001) overall SarQoL scores, and thus also worse QoL, were observed between
robust [77.1 (64.35–85.90)], pre-frail [62.54 (53.33–69.57)], and frail [49.99 (40.45–56.06)] participants. Six of the SarQoL
domains performed likewise, with significantly lower scores according to frailty status with Domain 7 (fears) being the
exception. Internal consistency was good (α = 0.866). Convergent (using Short-Form 36-Item and EQ-5D) and divergent
construct validity (using EQ-5D) was confirmed. Test–retest reliability was excellent [intraclass correlation coefficient = 0.918
(0.834–0.961)], with a standard error of measurement of 3.88 and a smallest detectable change of 10.76 points. We found
moderate responsiveness when five of the nine hypotheses were confirmed, coupled with a large effect size for the overall
SarQoL score (corrected standardized response mean of 1.44).
Conclusions The SarQoL questionnaire has adequate clinimetric properties for use with frail patients in clinical practice and
trials and could provide data that are more appropriate and detailed than the generic questionnaires currently used.
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Introduction
The World Health Organization declared the period from
2020 to 2030 to be the decade of healthy ageing, which they
define as ‘the process of developing and maintaining the
functional ability that enables wellbeing in older age’.1 This
concept is closely linked to the syndrome of frailty, a clinically
recognizable state of increased vulnerability in older people,
caused by age-related losses in physiological reserves and
function across multiple organ systems, such that the ability
to cope with everyday or acute stressors is compromised.2
This state of increased vulnerability is associated with
negative health outcomes, as evidenced by a recent meta-
analysis, which found an increased likelihood of premature
mortality, hospitalization, and institutionalization.3 Frailty
was also associated with an increased risk for developing dis-
ability in both basic and instrumental activities of daily living,
an increased risk for physical limitations, dependency, falling,
fractures, cognitive decline, decline in lean body mass, and
lower life satisfaction.3 These outcomes, in combination with
an estimated prevalence of 10.7–18%, mean that frailty rep-
resents an important burden on public health.4–6
While hard outcomes such as mortality and hospitaliza-
tions remain the primary indicators in research settings, out-
comes measuring the subjective experience of patients are
becoming as essential part of the arsenal. Health-related
quality of life is one of the main patient-reported outcome
measures used in research, and several studies have already
focused on quality of life (QoL) in frailty in the last decade.
A 2019 systematic review listed 22 studies that assessed
QoL in frailty and which demonstrated that frail participants
had worse QoL than robust participants. However, these dif-
ferences between frail and robust people were only clear
for the sub-concepts of physical functioning and satisfaction
with life. For social and environment scales, results were in-
consistent between the different questionnaires used, limit-
ing their usefulness in assessing the psychosocial well-being
pre-frail and frail individuals. In this systematic review, the
Short-Form 36-Item (SF-36) was the most frequently used in-
strument out of the 14 instruments included, followed by the
WHOQOL-BREF, the CASP-19, and the EUROHIS-QOL.7 Several
observations can be made from the results of this systematic
review. First, the SF-36, which was the most frequently used
instrument to measure QoL in frailty, is a generic instrument
and not adapted to specific populations or diseases.8 While
generic instruments allow QoL to be compared between a
range of populations, specific instruments often possess
better construct validity and are more sensitive to changes
in QoL over time.9 Secondly, the concept of QoL and the
components needed to provide a holistic assessment were
interpreted differently between each of the QoL question-
naires. While some concepts from the generic QoL question-
naires mentioned previously are shared with the sarcopenia
quality of life (SarQoL®) questionnaire (i.e. physical and
mental health and activities of daily living), others such as
‘body composition’, ‘leisure activities’, and ‘fears’ are unique.
The systematic review did not include frailty-specific QoL
instruments. A QoL instrument specific to the frailty syndrome
might improve sensitivity to change in disease-specific QoL
over time in this group.10
One such specific questionnaire is the SarQoL question-
naire, developed in 2015 with the aim of measuring
health-related QoL in sarcopenic persons.11 The question-
naire was constructed using input from experts, literature re-
view, and crucially, interviews with older, sarcopenic
individuals. It has been validated for use with sarcopenic,
older, community-dwelling participants in multiple languages
and has consistently been shown to be a valid and reliable in-
strument, as well as responsive to changes in QoL.12–21
Multiple authors have argued that the conceptual frame-
works of frailty and age-related sarcopenia overlap substan-
tially, notably on the similar clinical manifestations used to
diagnose the two conditions. The slowness indicator in the
Fried criteria for frailty and the low gait speed indicator used
to characterize muscle function in sarcopenia are one area of
overlap between the two conditions. Partial overlap exists
between weight loss in frailty and muscle loss in sarcopenia,
and fatigue/exhaustion in frailty and grip strength in
sarcopenia. Some have argued that sarcopenia is equivalent
to the physical component of frailty, separate from the cogni-
tive, psychological, sociological, and spiritual components of
frailty.22–24
Because of the overlap between sarcopenia and physical
frailty, we considered it worthwhile to explore whether the
SarQoL questionnaire could be used in the assessment of
QoL in frail and pre-frail individuals, as diagnosed with the
Fried criteria. This study aims to examine the clinimetric
properties of the SarQoL questionnaire in robust, pre-frail,
and frail participants of the Sarcopenia and Physical impair-
ment with advancing Age (SarcoPhAge) study.
Methods
Population
The analyses described in this manuscript have been carried
out using the data collected during the SarcoPhage study.
This cohort study followed a sample of community-dwelling
older people for 5 years and has been described in multiple
publications 25–29. In brief, the SarcoPhAge study recruited a
convenience sample of volunteers aged 65 years or older
living in the Liège province of Belgium. Participants were
recruited from different departments of an outpatient clinic
in Liège, as well as through advertisement in the local press.
Candidates were not eligible for inclusion in the cohort if they
presented with a body mass index (BMI) >50 kg/m2 or if they
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had one or more amputated limbs. No other exclusion
criteria were applied. Participants were invited to the re-
search centre once yearly, where they performed physical
tests and completed questionnaires.25 For the analyses pre-
sented here, we used data from Year 1 of follow-up, except
for the evaluation of the responsiveness of the questionnaire,
where we used data from the visits carried out at 1 and
5 years into the study.
Frailty evaluation
In the SarcoPhAge sample, physical frailty was evaluated with
the criteria described by Fried et al.30 The Fried diagnostic
criteria evaluate five items to determine whether a person
is considered to be robust, pre-frail, or frail. In this study,
the five criteria were measured with the following instru-
ments: weakness was present if handgrip strength measured
with hydraulic dynamometer was below the cut-offs based
on gender and BMI, low gait speed was detected by evaluat-
ing usual walking speed on a 4 m track (results corrected to
4.5 m track) with cut-offs based on gender and height, low
physical activity was measured with the Minnesota Leisure
Time Activity Questionnaire31 using gender-specific cut-offs
for kilocalories used in physical activity in the preceding
week, exhaustion was established using two items from the
Center for Epidemiological Studies Depression scale,32 and
weight loss was detected through a self-reported question
on unintentional weight loss of more than 4.5 kg in the past
year.25,30 For each item, participants were given 1 point if be-
low the cut-off, and 0 if not, and these item scores were
summed for a frailty score between 0 and 5. Participants with
zero points were considered robust, a score of 1 or 2 points
indicated a pre-frail state, and subjects with a score of 3 or
more points were considered to be frail. A detailed descrip-
tion of the criteria, instruments, and cut-off values is pro-
vided in Supporting Information, Table S1.
Quality of life measurement
The SarQoL questionnaire, the focus of this validation study, is
a patient-reported outcome measure specifically designed to
evaluate QoL in older, sarcopenic, community-dwelling peo-
ple. There are 55 items in the questionnaire, categorized into
seven domains of health-related dysfunction: (i) physical and
mental health, (ii) locomotion, (iii) body composition, (iv)
functionality, (v) activities of daily living, (vi) leisure activities,
and (vii) fears. A score between 0 (worst QoL) and 100 (best
QoL) is provided for each domain, and an overall QoL score
(range: 0–100 points) is calculated on the entirety of the
questionnaire.11 The scoring algorithm is not publicly
available, but tools to calculate the scores are available upon
request via info@sarqol.org or via the website www.sarqol.
org and free for non-sponsored research. The questionnaire
is self-reported and takes about 15 min to complete. The
SarQoL questionnaire has been validated in multiple
languages and has been shown to be a valid and reliable
instrument.13,15–19,33 The questionnaire was shown to be
responsive to changes in QoL in a sample of 42 sarcopenic
subjects followed over 3 years, and its standard error of
measurement (SEM) and smallest detectable change have
been calculated in different European populations as well as
pooled.20,21
Complementary to the SarQoL questionnaire, two generic
QoL questionnaires were also completed by each participant
to allow the evaluation of the construct validity of the SarQoL
questionnaire. The first of these, the SF-36 questionnaire,
measures functional health and well-being from the patient’s
perspective, providing eight domain scores (physical func-
tioning, social functioning, role functioning physical, role
functioning emotional, vitality, bodily pain, mental health,
and general health) and two summary scores (physical and
mental), all scored from 0 (worst QoL) to 100 (best QoL)
points.34 Secondly, the EuroQoL 5-Dimension 3-Level
(EQ-5D-3L) and the associated visual analogue scale (EQ-VAS)
were administered. The EQ-5D is a generic measure of health
status, which records self-reported problems (none, some,
and extreme) on five dimensions (mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression).35
Results are reported as an index score (between 0 and 1, with
0 indicating death and 1 indicating perfect health) and a
self-rated health evaluation (between 0, worst imaginable
health, and 100, best imaginable health).36
Clinimetric properties
The measurement properties to be included in this validation
were selected based on the COSMIN taxonomy and its re-
lated documentation.37,38 These include known-groups valid-
ity (also known as discriminative power), internal consistency,
construct validity (through hypotheses testing), reliability
(test–retest), measurement error, and responsiveness. We
also looked at the presence of floor and/or ceiling effects
and provided the smallest detectable change to aid in the in-
terpretation of the evolution of the SarQoL scores over time.
i Known-groups validity is based on the hypothesis that two
or more groups with distinctive characteristics should log-
ically differ in the construct that is measured.39 In the con-
text of this study, the hypothesis is that robust
participants should have higher QoL scores than pre-frail
and frail participants, which would mean that the SarQoL
questionnaire can discriminate between the three frailty
profiles.
ii Internal consistency quantifies the degree of interrelated-
ness between the items in the questionnaire, that is,
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whether all items in the SarQoL measure the same under-
lying construct (QoL).37,38
iii Construct validity is used to assess whether the question-
naire under investigation actually measures what it theo-
retically aims to measure. This is performed by
comparing the questionnaire with other questionnaires
(or subscales of) that should, in theory, measure the same
construct (convergent validity) or a different construct
(divergent validity).37,38 In this study, we utilized the same
eight hypotheses on the strength of association between
the overall QoL score of the SarQoL questionnaire and do-
mains of the SF-36 and EQ-5D that were used in previous
validations.13–19,33
iv The test–retest reliability of the questionnaire shows
whether the scores measured by the SarQoL question-
naire remain stable between multiple administrations,
on the condition that the participants’ health state also re-
mains stable.37,38 To measure this, the SarQoL question-
naire was administered twice, with an approximate
interval of 2 weeks in between, and participants provided
information on the stability of their health. Because of the
different objectives of the study that collected the data
analysed in this article, only the 43 participants who were
diagnosed as sarcopenic with the European Working
Group on Sarcopenia in Older People criteria were invited,
at the time of the original validation study, to participate
in the retest part, with 30 providing usable data.13
ReliabilityJCSM_12687 is also demonstrated by the SEM,
which provides a measure of the dispersion of observed
scores around the ‘true’ score from repeated
measurements. The smallest detectable change provides
the value for the minimum change in QoL scores that
needs to be observed to be certain that the measured
change in QoL is real and not possibly due to measure-
ment error.38
v Floor and ceiling effects indicate that the range of the scale
is too narrow and that extreme profiles cannot be accu-
rately measured. They are present when >15% of the par-
ticipants obtain either the highest or lowest score.
vi The last clinimetric property investigated was the respon-
siveness of the questionnaire, that is, its capacity to de-
tect change over time, between the first and fifth years
of the SarcoPhAge study.21 We used the same methodol-
ogy as in a previous evaluation of the responsiveness of
the SarQoL, which was combination of hypothesis testing
and effect size evaluation.21 In short, we evaluated nine
hypotheses (see Table 5) on the theorized strength of
correlation between the changes observed with the
SarQoL questionnaire between Year 1 and Year 5 and
the changes observed with (domains of) the SF-36,
EQ-5D, and EQ-VAS. The results were interpreted with
the criteria from de Boer et al., which indicate that a
questionnaire has high responsiveness if at least 75% of
hypotheses are confirmed, moderate when at least
50–75% are confirmed, and poor responsiveness when
less than 50% are confirmed.40 In this analysis, we
included all participants for whom we had valid data at
Year 1 and Year 5. For the second method, we calculated
standardized response means (SRMs) (a measure of
effect size), which reflect the magnitude of change
measured by the SarQoL and by the other questionnaires
used in this study. Larger effect sizes indicate that the
questionnaire possesses better responsiveness.41
Because this method is based on the assumption that a
change in health status has occurred, we could only
include those participants for whom we had valid data
at Year 1 and Year 5 and whose frailty status changed
in the years between evaluations. The change in frailty
status is used here as a proxy measure of change in
health status, and we hypothesize that a change in frailty
status will be reflected in the observed change in QoL.
Statistical analysis
Normality of distribution for quantitative variables was
tested with the Shapiro–Wilk test, by comparing mean and
median and by evaluating the histogram and Q–Q plot. Con-
tinuous variables following a Gaussian distribution are re-
ported as mean ± standard deviation, while those who do
not are reported as median (25th–75th percentile). Nominal
variables are reported as absolute (n) and relative (%)
frequencies. The evaluation of differences between groups
for nominal variables was carried out using Pearson’s χ2 test.
All results were considered significant at 5% level (P ≤ 0.05),
except for pairwise comparisons between the robust, pre-
frail, and frail groups, which were considered significant at
P ≤ 0.017 (P-value adjusted for the number of comparisons:
α = 0.05/3). IBM SPSS Statistics Version 25 for Windows
(IBM Corp., Armonk, NY) was used for all statistical
manipulations.
i Analysis of continuous variables to determine the
known-groups validity between the three frailty catego-
ries was carried out with the analysis of variance test if
distributions in all groups were Gaussian and with the
Kruskal–Wallis test if they were not. Paired comparisons
were carried out with multinomial regression analysis, so
as to obtain P-values for the differences between the ro-
bust, pre-frail, and frail groups.
ii Internal consistency was determined with Cronbach’s al-
pha test, where a value between 0.70 and 0.95 indicates
good internal consistency.42
iii Associations between two continuous variables (such as
used in the hypotheses for evaluating construct validity
and responsiveness) were examined with Pearson’s or
Spearman’s correlations, depending on normality of
distribution.
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iv The test–retest reliability was quantified by calculating the
intraclass correlation coefficients (ICCs) (two-way mixed
model  absolute agreement type) between the scores
from the first and the second administrations. ICCs greater
than 0.7 indicate acceptable reliability.38 The SEM was
calculated by dividing the standard deviation of the
difference between the scores from the first
administration and those of the second administration
by the square root of 2. This gives the following formula:
SEM = (SD(test score  retest score)∕√2). The smallest
detectable change is derived from the SEM value, by the
following formula: 1.96 * √2 * SEM.
v Floor and ceiling effects were evaluated following inspec-
tion of the frequency tables.
vi Finally, SRMs, a measure of effect size and used to evaluate
responsiveness, were calculated by dividing the mean dif-
ference between the SarQoL scores from the first year
and the fifth year of the SarcoPhAge study by the standard
deviation of the differences between these paired values.
The SRM values were subsequently transformed with the
formula SRM/ √2∕√(1  r), where ‘r’ signifies the correla-
tion between Year 1 and Year 5 scores.43 The corrected
SRM values can now be interpreted with the thresholds
formulated by Cohen et al., where SRM< 0.20 is trivial ef-
fect, 0.20 ≤ SRM < 0.50 is a small effect,
0.50 ≤ SRM < 0.80 is a moderate effect, and SRM ≥ 0.80
is considered a large effect.44
Results
Clinical characteristics
In total, 382 subjects were eligible for inclusion at the first
follow-up visit of the SarcoPhAge study. These subjects had
a median age of 73 (69–78) years old, were slightly over-
weight at a median BMI of 27 (24–30) kg/m2, took a median
of 5 (3–8) drugs, and had a median of 4 (3–5) co-morbidities.
There were slightly more women (n = 223; 58.4%) than men
in the sample. The median grip strength was 39 (33–45) kg
for men and 21 (17.5–25) kg for women. Lastly, the median
gait speed in the complete sample was 1.09 (0.91–1.28) m/s.
All 382 participants were evaluated for frailty with the
Fried criteria, and we found 172 (45%) robust, 167 (44%)
pre-frail, and 43 (11%) frail individuals. Clinical characteristics
were significantly different between these three groups. Frail
participants were older than pre-frail participants, who, in
turn, were older than robust individuals (P < 0.001). The
same dynamic was present for BMI (with frail participants
having the highest BMI; P < 0.001), drug consumption (with
frail participants taking the most drugs; P < 0.001), and
co-morbidities (with frail participants having the highest
number of co-morbidities; P < 0.001). As expected, frail
participants had lower grip strength than pre-frail partici-
pants, who, in turn, had lower grip strength than robust peo-
ple (P < 0.001 for men and women). The same was observed
for gait speed (with frail participants having the lowest gait
speed; P < 0.001). Detailed results and pairwise comparisons
are available in Table 1.
Known-groups validity
The overall QoL score measured by the SarQoL questionnaire
was significantly different (P < 0.001) between the three cat-
egories of frailty, following a downward trend with robust
participants having the best QoL [77.10 (64.35–85.90)],
followed by the pre-frail participants [62.54 (53.33–69.57)]
and with the frail participants presenting with the worst
QoL [49.99 (40.45–56.06)]. The differences between the over-
all QoL scores in these three groups were revealed to be sig-
nificant in the paired comparisons (all P < 0.001).
The QoL scores for the seven domains of health-related
quality of life in the SarQoL questionnaire were also shown
to be highly significantly different (P < 0.001). An examina-
tion of the paired differences showed that only Domain 7
(fears) was not significantly different in the comparison be-
tween pre-frail and frail groups (P = 0.119).
The complete results of the known-groups validity are pre-
sented in Table 2.
Internal consistency
The homogeneity of the questionnaire was found to be excel-
lent, with Cronbach’s alpha of 0.866, at the upper end of the
0.70 to 0.95 range considered good. This shows that the
questionnaire is consistent without showing the increased
likelihood for redundancy associated with alpha values
greater than 0.95. The influence of individual domains was
tested by deleting a single domain at a time. The resulting al-
pha values ranged from 0.854 to 0.894, indicating that no do-
main unduly influences the internal consistency.
Construct validity
Two sets of hypotheses were examined: for the convergent
construct validity, we theorized that the overall QoL score
of the SarQoL questionnaire measures a construct related
to the SF-36 physical functioning, role limitation due to phys-
ical problems, and vitality domains as well as to the EQ-5D
utility score. We therefore expect to find moderate to strong
correlations between the SarQoL and these domains. For the
divergent construct validity, we theorized that the overall
QoL score of the SarQoL questionnaire measures a different
construct than the SF-36 role limitation due to emotional
problems and mental health domains, as well as the self-care
Evaluating quality of life in frailty 5


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 A. Geerinck et al.
Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12687
and anxiety/depression items of the EQ-5D. If this is correct,
we expect to find weak or non-existent correlations between
the SarQoL and these domains.
The convergent validity of the SarQoL questionnaire in
the entire sample was excellent, as evidenced by the con-
firmation of the four pre-specified hypotheses and the
strong correlations between the overall QoL score of the
SarQoL questionnaire and the four domains theorized to
measure similar constructs (correlation coefficients be-
tween 0.447 and 0.798). When isolating the three frailty
groups, the results were largely similar, with the exception
of the correlation between the SarQoL and the SF-36 role
limitation due to physical problems domain in the frail
group, which dropped from r = 0.628 (P < 0.001) to
r = 0.246 (P = 0.199).
The results of the divergent construct validity were less
straightforward: both in the complete sample and in the
three frailty categories, we found moderate to strong correla-
tions between the SarQoL questionnaire and the two
domains of the SF-36 theorized to be measuring a different
construct. The hypotheses with the EQ-5D self-care and anx-
iety/depression items were confirmed by weak correlations
(respectively, r = 0.273; P < 0.001 and r = 0.257;
P < 0.001).
The full results, shown in Table 3, demonstrate that six out
of the eight pre-specified hypotheses were confirmed, fulfill-
ing the criteria of 75%, which indicates acceptable construct
validity.
Reliability
One of the 30 participants was not evaluated for physical
frailty, which means that test–retest data were available for
29 participants, of which 4 (13.8%) were robust, 18 (62.1%)
were pre-frail, and 7 (24.1%) were frail. An ICC of 0.918
[95% confidence interval (CI) = 0.834–0.961] was found for
the overall QoL score of the SarQoL questionnaire,
demonstrating excellent test–retest reliability. The ICCs for
the individual domains showed acceptable (ICC > 0.7) reli-
ability for all but two domains: Domain 6, leisure activities
[ICC = 0.391 (95% CI = 0.029–0.660)], and Domain 7, fears
[ICC = 0.318 (95% CI = 0.055 to 0.612)]. Detailed results
for the test–retest reliability are reported in Table 4.
The SEM in this sample was calculated to be 3.88 points,
leading to a smallest detectable change of 10.76 points. In
practical terms, the overall QoL score of an individual partic-
ipant would have to change by 10.76 points to be able to be
sure that the observed change in QoL is due to a real change
in QoL in the patient. SEM and smallest detectable change for
the individual domains are reported in Table 4.
Floor and ceiling effects
None of the 382 participants obtained the lowest (0) or the
highest (100) score possible for the overall QoL score of the
SarQoL® questionnaire, showing the absence of floor and ceil-
ing effects in the summary score.
Responsiveness
Out of the 382 participants who provided usable data at the
first year of the SarcoPhAge study, 235 remained in the study
at the fifth year of follow-up and were included in the respon-
siveness evaluation. Of these 235, a further 117 changed in
terms of their frailty status between the first and fifth years
of the study, and these were included in the analysis of re-
sponsiveness through the evaluation of effect size (SRMs).
We examined nine hypotheses used in an earlier study of
the responsiveness of the SarQoL questionnaire, on the theo-
rized correlation between changes measured by the SarQoL
questionnaire and by other questionnaires. We were able to
confirm five out of nine hypotheses but had to reject Hypoth-
esis 1 (ΔSarQoL overall score and ΔSF-36 general health), Hy-
pothesis 4 (ΔSarQoL overall score and ΔEQ-VAS), Hypothesis
Table 3 Construct validity of the SarQoL® questionnaire in frailty
Robust (n = 172) Pre-frail (n = 167) Frail (n = 43) All (n = 382)
r P r P r P r P
Convergent validity
SF-36 physical functioning 0.761 <0.001 0.693 <0.001 0.608 <0.001 0.798 <0.001
SF-36 role limitation physical 0.408 <0.001 0.611 <0.001 0.246 0.199 0.628 <0.001
SF-36 vitality 0.595 <0.001 0.499 <0.001 0.695 <0.001 0.678 <0.001
EQ-5D utility score 0.305 <0.001 0.311 <0.001 0.564 0.001 0.447 <0.001
Divergent validity
SF-36 role limitation emotional 0.400 <0.001 0.473 <0.001 0.015 0.936 0.503 <0.001
SF-36 mental health 0.588 <0.001 0.489 <0.001 0.392 0.035 0.554 <0.001
EQ-5D self-care a a 0.207 0.011 0.278 0.145 0.273 <0.001
EQ-5D anxiety/depression 0.161 0.070 0.222 0.010 0.489 0.007 0.257 <0.001
aAll 172 robust subjects responded identically on the EQ-5D self-care question.
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5 (ΔSarQoL Domain 1 and ΔSF-36 general health), and Hy-
pothesis 6 (ΔSarQoL Domain 1 and ΔEQ-VAS). According to
the criteria formulated by De Boer et al., this indicated that
the SarQoL questionnaire possesses moderate responsive-
ness because 45% of the hypotheses have been refuted.
The details of the hypotheses and the observed correlations
can be found in Table 5.
We also evaluated responsiveness with the metric of effect
size. We calculated SRMs for all domains and summary scores
of the SarQoL, SF-36, and EQ-5D questionnaires. The com-
plete results are reported in Table 6. We can observe that
the SRM of the SarQoL overall score (corrected
SRM = 1.14) is much larger than the SF-36 PCS (corrected
SRM = 0.634), the EQ-5D index (corrected SRM = 0.064),
and the EQ-VAS (corrected SRM = 0.267). Globally, the
SarQoL questionnaire had small effect sizes for three domain
scores, moderate for 2 and large for 1. The SF-36 obtained
small effect sizes for five domains and the MCS, and moder-
ate effect sizes for three domains and the PCS.
Discussion
This study examined whether the SarQoL questionnaire could
be used as a disease-specific instrument to measure
health-related QoL in frailty. The psychometric results pre-
sented in this article indicate that it has adequate measure-
ment properties when used with the Fried frailty criteria.
This means that the SarQoL could be a new option for re-
searchers seeking to evaluate QoL in populations character-
ized by the presence of pre-frailty and/or frailty.
This study demonstrated that the SarQoL questionnaire
can discriminate between robust, pre-frail, and frail subjects,
with declining QoL scores according to the category of
frailty, and that it can do so over a wide range of concepts.
The systematic review by Crocker et al. highlighted that
(sub)scales measuring physical aspects of QoL were broadly
able to discriminate between robust and frail people but re-
ported inconsistent results for other aspects of QoL.7 There-
fore, it is encouraging to see that the SarQoL questionnaire
Table 4 Test–retest reliability of the SarQoL® questionnaire in frailty
ICC 95% CI SEM SDC
Domain 1: physical and mental health 0.764 0.558–0.881 7.06 19.57
Domain 2: locomotion 0.850 0.706–0.926 7.92 21.94
Domain 3: body composition 0.700 0.454–0.847 8.81 24.41
Domain 4: functionality 0.879 0.759–0.941 5.50 15.25
Domain 5: activities of daily living 0.812 0.638–0.907 6.78 18.80
Domain 6: leisure activities 0.391 0.029–0.660 13.82 38.30
Domain 7: fears 0.318 0.055 to 0.612 14.32 39.68
Overall QoL score 0.918 0.834–0.961 3.88 10.76
CI, confidence interval; ICC, intraclass correlation coefficient; QoL, quality of life; SDC, smallest detectable change; SEM, standard error of
measurement.









1. ΔSarQoL® overall score and ΔSF-36 general
health domain are correlated.
r > 0.4 0.389a <0.001 Rejected
2. ΔSarQoL® overall score and ΔSF-36 vitality
domain are correlated.
r > 0.3 0.460b <0.001 Confirmed
3. ΔSarQoL® overall score and ΔSF-36 physical
functioning domain are correlated.
r > 0.5 0.690a <0.001 Confirmed
4. ΔSarQoL® overall score and ΔEQ-VAS are correlated. r > 0.4 0.226a <0.027 Rejected
5. ΔSarQoL® Domain 1 (physical and mental
health) and ΔSF-36 general health domain are correlated.
r > 0.3 0.139a 0.176 Rejected
6. ΔSarQoL® Domain 1 (physical and mental health)
and ΔEQ-VAS are correlated.
r > 0.3 0.142a 0.166 Rejected
7. ΔSarQoL® Domain 2 (locomotion) and ΔSF-36
physical functioning domain are correlated.
r > 0.4 0.539a <0.001 Confirmed
8. ΔSarQoL® Domain 4 (functionality) and ΔSF-36
physical functioning domain are correlated.
r > 0.5 0.601a <0.001 Confirmed
9. ΔSarQoL® Domain 5 (activities of daily living)
and ΔSF-36 physical functioning domain are correlated.
r > 0.5 0.617a <0.001 Confirmed
Δ = change over 4 years.
aSpearman correlation.
bPearson correlation.
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is able to discriminate on more than just the physical as-
pects of QoL and that it brings extra precision in being able
to discriminate between robust, frail, and pre-frail individ-
uals. A note of caution is warranted with regard to Domain
7, where only the comparison between robust and frail par-
ticipants yielded significantly different QoL scores. This do-
main should not be interpreted in a vacuum but taking
into account the other domain scores and the overall QoL
score.
The internal consistency was shown to be high (α = 0.866),
indicating that the domains in the questionnaire are highly in-
terrelated and measure the same construct, QoL. Mixed re-
sults were obtained in the evaluation of the construct
validity of the questionnaire. All four hypotheses on the con-
vergent validity were confirmed, but two out of the four hy-
potheses for divergent validity were rejected. The two
rejected hypotheses, where we found stronger correlations
than expected, were between the overall QoL score of the
SarQoL questionnaire and the mental health and role limita-
tions due to emotional problems domains of the SF-36. It
may be that our hypotheses are erroneous and that these
two domains are conceptually closer to the SarQoL question-
naire than we theorized. One correlation of particular inter-
est is between the SarQoL overall QoL score and the SF-36
role limitation due to physical limitations in the frail group
(r = 0.246), because it is significantly lower than the correla-
tion coefficients in the robust (r = 0.408) and pre-frail groups
(r = 0.611). Upon further investigation, this discrepancy is
linked to the significant floor effect in this SF-36 domain,
where 16 of the 30 participants obtain the lowest score
possible.
The test–retest reliability of the questionnaire was excel-
lent, with an ICC of 0.918 (95% CI = 0.834–0.961) for the over-
all score. However, because the original study only contacted
the participants diagnosed as sarcopenic with the European
Working Group on Sarcopenia in Older People criteria to en-
ter the evaluation of the test–retest reliability, there were
only data available for 29 participants. So, while this is a re-
sult that indicates good test–retest reliability, with an ele-
vated ICC and a relatively small CI, these results should be
confirmed in a larger sample and in particular samples with
sufficient pre-frail and frail participants to calculate ICC’s for
these particular groups. Because the SEM and the smallest
detectable change are based on the test–retest data, this
same remark also applies to these two indicators. It should
also be noted that, in this study, Domain 6 (leisure activities)
and Domain 7 (fears) did not demonstrate adequate reliabil-
ity. We hypothesize that this may because of the low sample
size in combination with the low number of items for these
two domains (two items for Domain 6 and four items for Do-
main 7), which causes any difference between the responses
between the first and second administration of the question-
naire to be exaggerated in the scores.
We examined the ability of the SarQoL questionnaire to
detect a change in QoL. We found moderate responsiveness
through the confirmation of five out of nine hypotheses on
the correlation between changes in QoL observed by the
SarQoL questionnaire and by other questionnaires. It is
Table 6 Standardized response means
Domains Corrected SRM Interpretationa
1. ΔSarQoL® D1 physical and mental health 0.383 Small
2. ΔSarQoL® D2 locomotion 0.755 Moderate
3. ΔSarQoL® D3 body composition 0.315 Small
4. ΔSarQoL® D4 functionality 0.940 Large
5. ΔSarQoL® D5 activities of daily living 0.883 Large
6. ΔSarQoL® D6 leisure activities 0.255 Small
7. ΔSarQoL® D7 fears 0.070 Trivial
8. ΔSarQoL® overall score 1.144 Large
9. ΔSF-36 physical functioning 0.749 Moderate
10. ΔSF-36 social functioning 0.204 Small
11. ΔSF-36 role limitations due to physical health 0.301 Small
12. ΔSF-36 role limitations due to emotional problems 0.251 Small
13. ΔSF-36 mental health 0.274 Small
14. ΔSF-36 vitality 0.577 Moderate
15. ΔSF-36 bodily pain 0.490 Small
16. ΔSF-36 general health 0.693 Moderate
17. ΔSF-36 physical component summary 0.634 Moderate
18. ΔSF-36 mental component summary 0.224 Small
19. ΔEQ-5D utility index 0.064 Trivial
20. ΔEQ-VAS 0.267 Small
SRM, standardized response mean.
SRMs are calculated by dividing the mean difference between scores from the first year and the first year by the standard deviation of the
differences between these paired values. The SRM values were subsequently corrected with the formula SRM∕√2∕√(1  r), where ‘r’ sig-
nifies the correlation between Year 1 and Year 5 scores. Δ = change over 4 years.
aInterpretation of corrected SRMs: 0.20 ≤ SRM < 0.49 = small change; 0.50 ≤ SRM < 0.79 = moderate change; and SRM ≥ 0.80 = large
change.
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possible that the rejection of several hypotheses is linked to
the lower SRMs found between the different questionnaires.
In fact, the SRM of the overall QoL score of the SarQoL ques-
tionnaire is markedly stronger at SRM = 1.144 compared
with the strongest effect size of the SF-36, which was the
physical functioning subscale at SRM =0.749. It may be that
the rejection of some hypotheses was thus caused not by
poor responsiveness of the SarQoL questionnaire but by
smaller effect sizes found by the SF-36. Similarly, for the
EQ-VAS, we found a small effect at SRM = 0.267 and the re-
jection of two hypotheses associated with this instrument.
Here also, this may be more linked to the performance of
the EQ-VAS in combination with the 4 year interval between
the assessments. It is highly likely that an instrument such as
the EQ-VAS would be influenced by response shift, which is
defined as a change in the self-evaluation of the meaning of
a target construct caused by reconceptualization of the con-
struct, a reprioritization of the participants’ values, or a recal-
ibration of the respondents’ internal standards of
measurement.38,45 Overall assessments, such as the EQ-VAS,
which asks the respondent to indicate on a scale from 0 to
100 ‘how good or bad your health state is today’, are more
vulnerable to response shift because they require careful
consideration and interpretation of the question. The partic-
ipants had to evaluate for themselves the meaning of the
concept ‘health state’ and what is considered ‘good’ and
‘bad’ and assign a numerical value to this, leaving open the
possibility of reconceptualization, reprioritization, or
recalibration.46 Researchers investigating changes in QoL
over time or pre-intervention/post-intervention should make
the overall QoL score of the SarQoL questionnaire their main
outcome, given that it has the highest SRM and the smallest
detectable change. If a significant change in overall QoL is
found, further analyses of the individual domains could be
useful in indicating on what domains a participant’s QoL
has changed.
Because this study used data collected during a previous
study, we were unable to investigate and quantify the con-
tent validity of the SarQoL questionnaire in a population of
frail, older, community-dwelling individuals. In the develop-
ment of the questionnaire, content validity had been put at
the heart of the process by soliciting, at each step of the item
generation and selection process, input from multiple
sarcopenic persons.11 In this study, we were unable to pro-
vide this information from frail individuals. However, some
authors have theorized that sarcopenia, the target condition
for which the SarQoL questionnaire was developed, consti-
tutes one of the main components of the clinical frailty syn-
drome, all the while recognizing that frailty should not be
limited to physical manifestations but should also incorporate
psychological, cognitive, emotional, social, and spiritual
factors.24,47 Currently, to our knowledge, the only question-
naire that measures QoL and that is specifically designed with
and for older frail persons is the Geriatric Quality of Life
Questionnaire.48 However, the developers left the definition
of what constitutes the ‘frail elderly’ up to the appreciation
of the clinicians responsible for recruitment, instead of a rec-
ognized diagnostic tool. While the SarQoL questionnaire was
not specifically developed for frailty, the shared characteris-
tics between sarcopenia and frailty mean that it should be
able to provide a precise measurement of the physical weak-
ness aspect of frailty. Apart from the physical domains, the
SarQoL has also incorporated items on mental health, body
image, sexuality, activities of daily living, leisure activities,
and fears, making for a multidimensional framework of QoL.
Healthy ageing is already high on the agenda for most
health systems in both Western and Asian countries and will
only gain in importance as the number of older people
increases.49 Concepts such as frailty, sarcopenia, or the con-
struct recently proposed by the World Health Organization
called Intrinsic Capacity, which is a composite of all the phys-
ical and mental capacities of an individual, may play an im-
portant role in any future medical approach.50 Whatever
approach is adopted, it must take in the perspective and pri-
orities of the target population, and QoL can be an important
metric for this. Having valid, reliable, and precise instruments
to measure QoL that can pick up on the impact of a specific
target condition is a prerequisite to be able to rely on QoL in-
struments to provide information on the patients’ lived
experience.
There are some limitations to this study. First off, we
adopted the frailty criteria developed by Fried et al., but
other diagnostic approaches are available, such as the
Rockwood Clinical Frailty Scale or the IF-VIG, among
others.51–53 Although all these approaches purportedly mea-
sure the same concept, frailty, we cannot be sure that the
results on the validity and reliability of the SarQoL would
have been the same if we had applied other diagnostic ap-
proaches. Secondly, our sample of robust, pre-frail, and frail
participants is not necessarily representative of frailty in
the wider community. Because these data were collected
within a study that recruited volunteers, and which asked
those volunteers to make several trips to the research cen-
tre, it is likely that the SarcoPhAge study recruited a sample
that was in better overall condition, and that had better mo-
bility, than a representative sample of pre-frail and frail par-
ticipants. While this study has shown that the SarQoL
questionnaire is a valid and reliable tool in frailty, additional
investigations in samples with a different make-up need to
confirm these results. Lastly, while the overall sample size
was more than adequate for a psychometric study, the
test–retest sample is relatively small with only 29 partici-
pants. This steep reduction from the overall sample size is
a result of the fact that only a subset of participants was in-
vited to complete the questionnaire a second time. However,
because we have the 95% CI around the ICC, we can judge
that most values have adequate precision, apart from
Domains 6 and 7.
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In conclusion, the study evaluated the validity and reliabil-
ity of the SarQoL questionnaire in frailty and found that it is a
valid and reliable tool for the assessment of QoL. Because of
the shared mechanism of physical weakness between
sarcopenia and frailty, the SarQoL questionnaire can provide
more specific information on QoL in frailty than the generic
questionnaires available.
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